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Abstract: Universal hepatitis B vaccination of newborns was implemented in Russia starting from
1998. From 1998 to 2019, the incidence of acute hepatitis B reduced from 43.8 to 0.57 cases per
100,000 population. Here, we assessed the timely coverage of newborns with the birth dose (HepB-
BD), second dose (HepB-2nd), and three vaccine doses (HepB3) in two remote regions of Russia with
low (Belgorod Oblast) and high (Yakutia) levels of hepatitis B virus (HBV) endemicity. Vaccination
data were obtained from the medical records of 1000 children in Yakutia and 2182 children in Belgorod
Oblast. Sera of healthy volunteers from Belgorod Oblast (n = 1754) and Yakutia (n = 1072) across
all age groups were tested for serological markers of HBV to assess the infection prevalence and
herd immunity. Average HepB-BD coverage was 99.2% in Yakutia and 89.4% in Belgorod Oblast
(p < 0.0001) and in both regions varied significantly, from 66% to 100%, between medical centers. The
principal reason for the absence of HepB-BD was parent refusal, which accounted for 63.5% of cases of
non-vaccination (83/123). While timely HepB-2nd coverage was only 55.4%–64.7%: HepB3 coverage
by the age of one year exceeded 90% in both study regions. HBV surface antigen (HBsAg) prevalence
in the 1998–2019 birth cohort was 0.2% (95% CI: 0.01–1.3%) in Belgorod Oblast and 3.2% (95% CI:
1.9–5.2%) in Yakutia. The proportion of persons testing negative for both antibodies to HBsAg
(anti-HBs) and antibodies to HBV core antigen (anti-HBc) in the 1998–2019 birth cohort was 26.2%
(125/481) in Belgorod Oblast and 32.3% (162/501) in Yakutia. We also assessed the knowledge of
and attitude towards vaccination among 782 students and teachers of both medical and non-medical
specialties from Belgorod State University. Only 60% of medical students knew that hepatitis B is a
vaccine-preventable disease. Both medical and nonmedical students, 37.8% and 31.3%, respectively,
expressed concerns about safety and actual necessity of vaccination. These data indicate the need to
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introduce a vaccine delivery audit system, improve medical education with respect to vaccination
strategies and policies, and reinforce public knowledge on the benefits of vaccination.
Keywords: hepatitis B vaccine; birth dose coverage; HBV prevalence; hepatitis B epidemiology;
public health
1. Introduction
Hepatitis B caused by human hepatitis B virus (HBV) is a widespread, socially signifi-
cant infection causing up to 900,000 deaths annually, primarily due to the underlying liver
disease culminating in liver cirrhosis and hepatocellular carcinoma (HCC) [1]. Hepatitis
B can be prevented by vaccination. Highly effective recombinant vaccines have been
available since 1982 [2]. The most effective approach to control hepatitis B is universal
newborn vaccination, with the first dose administered 24 h after birth. As of 2015, the
hepatitis B neonatal vaccination program has been adopted in 185 countries [1]. In Russia,
this program was implemented in 1998 and implied the vaccination of all newborns by
standard immunization schedule (0, 1, and 6 months), except for children born to HBV
infected mothers, who are vaccinated with four vaccine doses (0, 1, 2 and 12 months). For
all newborns, regardless of mother’s HBV status, the first dose of vaccine is administered
within 24 h after birth. In addition, about 62.5 million people, including adults under the
age of 60, have been vaccinated under the National Priority Health Project launched in
2006. Within the framework of this project, free vaccination against hepatitis B was offered
to all children, adolescents and adults under the age of 60. As a result of the project, by
2013 the coverage by three doses of hepatitis B vaccine reached 97% in children under 18,
and 72% in adults aged 18–59 years [3]. This has led to a sharp decline in the incidence of
acute hepatitis B, in other words, the number of new HBV infections. Acute hepatitis B
incidence rates in the total population of Russia dropped from up-to 43 per 100,000 in the
pre-vaccination period to the lowest indicators of 0.9 per 100,000 in 2016–2018 and 0.6 per
100,000 in 2019. In children under 18 years of age, the incidence of acute hepatitis B is even
lower, 0.05–0.08 in 2017–2019 [4]. Despite being very low, these incidence rates speak of
vaccination gaps resulting in continuous HBV circulation with possible mother-to-child
transmission. Analysis of the effectiveness of the already implemented measures and
recommendations of additional interventions are needed to achieve the World Health
Organization (WHO) hepatitis elimination goals defined as 90% reduction in the incidence
and 65% reduction in the mortality compared with the baseline of 2015 [5].
During the last 10 years, the coverage of hepatitis vaccination in children in Russia
has been as high as 90%. However, this figure is based on the coverage with the complete
vaccination during the first year of life. It does not account for the coverage with the
most important first hepatitis B vaccine dose (birth dose; HepB-BD) [6]. The data on
this key indicator for interventions under the WHO global health sector strategy on viral
hepatitis [5] in Russia is limited.
The primary objective of our study was to determine the actual rates of coverage
with timely HepB-BD and the complete vaccination course in two regions of Russia, one
with a low level, and the other with a high level of HBV prevalence. The first, Belgorod
Oblast, is localized in the European, and the other, Sakha Republic (Yakutia), in the Asian
part of the country. Belgorod Oblast is typical of the European part of Russia in terms of
economic and demographic characteristics; the reported annual rates of acute and chronic
hepatitis B incidence are 20–40% lower than the average for the Russian Federation. In
Yakutia, a region spanning across a large area of Central and Northern Siberia, hepatitis B
presents a serious health care problem. In the pre-vaccination period, HBV prevalence in
Yakutia was 3–4 times higher than the average for the Russian Federation [7]. In 2017–2019,
the incidence of acute hepatitis B in Yakutia dropped to 0.2–0.4 per 100,000, however,
the annual rates of chronic hepatitis B are still very high (24.9 per 100,000 in 2019) [4],
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pointing at existence of a large reservoir of the potential sources of HBV infection of the
resident population.
Along with vaccination coverage in the studied regions, we assessed the prevalence
of markers of current and past HBV infection among a conventionally healthy population
in these regions in order to determine the epidemiological background and the impact of
vaccination coverage on HBV prevalence. In the same cohorts, we analyzed herd immunity
to HBV, both vaccine-induced, confirmed by the presence of antibodies to HBsAg (anti-
HBs) only, and post-infection, indicated by reactivity for both anti-HBs and antibodies to
HBV core antigen (anti-HBc), or for only anti-HBc. In addition, we conducted a survey of
university students and teachers (including but not limited to medical faculty) in one of
the study regions regarding their attitude to vaccination, to identify the factors that affect
coverage with vaccination in practice.
2. Materials and Methods
2.1. Analysis of Hepatitis B Vaccination Coverage in Newborns
The study analyzed the coverage with timely administration of HepB-BD (given
within 24 h after birth), timely administration of the second dose (HepB-2nd), given within
1–1.5 months after the timely birth dose, and the coverage with the complete three-dose
vaccination (HepB3) within the first year of life, in children born in Yakutia and Belgorod
Oblast, Russian Federation, during 2017–2018. The study design was approved by the
Ethics Committee of the Mechnikov Research Institute for Vaccines and Sera in Moscow,
Russia (Approval #1 dated 28 February 2018). Information about vaccination was obtained
from the randomly selected individual vaccination history cards or from the individual
copies of Form No.63 (a document that is generated for each child at his or her first visit to
a pediatric polyclinic based on data transmitted from maternity hospitals). Written consent
to participate in the study were signed by all parents of the vaccinated children.
Data were collected from three types of clinics, categorized based on their location:
(1) in the regional capital; (2) in the district centers; and (3) in the rural areas, further
referred to as city, town and rural clinics, respectively. In total, the study involved 10 clinics
in Belgorod Oblast (4 city and 6 town clinics) and 16 centers in Yakutia (4 city, 7 town and
5 rural clinics) (Figure 1). Hepatitis B vaccination data were collected for 2182 newborns
in Belgorod Oblast and 1000 newborns in Yakutia. The sample sizes represent 16.5% of
13,183 newborns in Belgorod Oblast, and 7.8% of 12,818 newborns in Yakutia (according
to Russian Statistics Agency (Moscow, Russia) [8]. For all cases of missed HepB-BD, the
reasons for non-vaccination, recovered from the medical records, were attributed to parents’
refusal or medical contraindications, and classified accordingly.
2.2. Serum Samples
The serum samples of 1754 healthy volunteers from Belgorod Oblast and 1072 healthy
volunteers from Yakutia were collected in 2018–2019, i.e., 20 years post the on-start of the
universal HBV vaccination of newborns in Russia. Both cohorts represent about 0.1% of the
total population of the respective regions (approximately 967,000 persons in Yakutia and
1,550,000 in Belgorod Oblast; Bulletin of the Russian Statistics Agency [9]. Participants of
the survey were selected randomly from persons undergoing routine medical examination,
visitors to the vaccine room for routine vaccinations, patients visiting the clinic for reasons
not related to infectious diseases. The population sample size was calculated for the
known size of the general population of study regions based on the previously published
data on HBV surface antigen (HBsAg) and anti-HBc prevalence rates in the Russian
Federation [10] with chosen power (80%) and confidence level (95%) [11]. Serological
survey was conducted according to the principles expressed in the Declaration of Helsinki.
Design of the serological study was approved by the Ethics Committee of the Mechnikov
Research Institute for Vaccines and Sera in Moscow, Russia (Approval #1 dated 2018-28-02).
Written informed consent was obtained from all study participants. Serum samples were
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coded and stored in aliquots at −70 ◦C until testing. After thawing, sera were tested for
the serological markers of HBV infection (Figure 1).




Figure 1. Study regions (in green) with indicated centers in each region where data on vaccination coverage were collected 
(B1 to B10–centers in Belgorod Oblast, Y1 to Y16–centers in Yakutia). The capital of each region is underlined. The number 
of participants in each step of the study (newborn vaccination coverage, serosurvey, survey of university students and 
teachers) are indicated in the callouts. 
2.2. Serum Samples 
The serum samples of 1754 healthy volunteers from Belgorod Oblast and 1072 
healthy volunteers from Yakutia were collected in 2018–2019, i.e., 20 years post the on-
start of the universal HBV vaccination of newborns in Russia. Both cohorts represent 
about 0.1% of the total population of the respective regions (approximately 967,000 per-
sons in Yakutia and 1,550,000 in Belgorod Oblast; Bulletin of the Russian Statistics Agency 
[9]. Participants of the survey were selected randomly from persons undergoing routine 
medical examination, visitors to the vaccine room for routine vaccinations, patients visit-
ing the clinic for reasons not related to infectious diseases. The population sample size 
was calculated for the known size of the general population of study regions based on the 
previously published data on HBV surface antigen (HBsAg) and anti-HBc prevalence 
rates in the Russian Federation [10] with chosen power (80%) and confidence level (95%) 
[11]. Serological survey was conducted according to the principles expressed in the Dec-
laration of Helsinki. Design of the serological study was approved by the Ethics Commit-
tee of the Mechnikov Research Institute for Vaccines and Sera in Moscow, Russia (Ap-
proval #1 dated 2018-28-02). Written informed consent was obtained from all study par-
ticipants. Serum samples were coded and stored in aliquots at −70 °C until testing. After 
thawing, sera were tested for the serological markers of HBV infection (Figure 1). 
The subjects were males or females aged 0–95 years, conditionally healthy people 
with no symptoms of acute disease at enrollment (self-reported or parent-reported) and 
permanent residents of the study regions. Exclusion criteria were acute illnesses, a body 
temperature over 37.1 °C or any surgery, blood transfusion or treatment with blood prod-
ucts within three months before enrollment into the study. The study included eight age 
cohorts, from children under 1 year to seniors over 60 years of age (0–9, 10–14, 15–19, 20–
Figure 1. Study regions (in green) with indicated centers in each region where data on vaccination coverage were collected
(B1 to B10–centers in Belgorod Oblast, Y1 to Y16–centers in Yakutia). The capital of each region is underlined. The number
of participants in each step of the study (newborn vaccination coverage, serosurvey, survey of university students and
teachers) are indicated in the callouts.
The subjects were males or females aged 0–95 years, conditionally healthy people
with no symptoms of acute disease at enrollment (self-reported or parent-reporte ) and
p rmanent residents f the st dy regions. Exclusion criteria wer acute illnesses, a body
tempera ure over 37.1 ◦C or any surgery, blood transfusion or treatment with blood prod-
ucts within three months before enrollment into th study. The study included eight age
c horts, from chil ren under 1 year t seniors over 60 years of age (0–9, 10–14, 15–19,
20–29, 30–39, 40–49, 50–59, and ≥60 years). The mean population sample size each ag
group was 219 individuals (90–382) in Belgorod Oblast and 153 (99–402) in Yakutia. The
male/female ratio varied fr m 1:0.8 to 1:2, depending on the ag cohort and study r gion.
The mean age of participants was 44.2 ± 22.8 years in Belg rod Oblast, and 27.9 ± 21.3
years in Yakutia. The rural/urban popul tion ratio was 1:6 both in Belgorod Oblast and
in Yakutia.
2.3. HBV Testing
All serum samples from conditionally healthy individuals were tested for HBs g,
anti-HBc and anti-HBs using commercially available enzyme-linked immunosorbent assay
(ELISA) kits (Vector-Best, Novosibirsk, Russia). The sensitivity of the HBsAg ELISA Kit,
according to the manufacturer’s specifications, was 0.01 IU/mL. Samples were considered
positive for anti-HBs if they contained antibodies in concentration of ≥10 mIU/mL. All
samples positive for HBsAg were tested for HBeAg and antibodies to the hepatitis D virus
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(anti-HDV) using ELISA kits from the same manufacturer. All testing was performed
according to the manufacturer’s instructions for the respective kits.
2.4. Survey of University Students and Teachers on Attitude to Vaccination
A total of 782 students and teachers of the Belgorod State University were interviewed
on their knowledge of and their attitude towards vaccination using a specially designed
questionnaire (Supplementary Figure S1). Of the participants, 88.9% were students and
11.1%, university teachers. The male/female ratio among participants was 1:1.6, the average
age was 22.5 ± 8.9 years (15–79 years). Among the participants, 147 students and 7 teachers
were affiliated to the Medical Faculty. Other specialties/disciplines were represented by
follows: Humanitarian (31 students and 8 teachers), Natural Science (75 students and
8 teachers), and Technical (360 students and 63 teachers). Participation in the survey was
voluntary and anonymous. All survey participants were interviewed verbally; answers
were entered into the questionnaire by the interviewer during the survey. The questionnaire
contained 12 questions regarding the responders knowledge about (i) vaccination in general,
the hepatitis B vaccine in particular; (ii) diseases that can be prevented by vaccination;
(iii) vaccines; and (iv) confidence in vaccination. Data collected by the questionnaire were
transferred into an Excel database and subjected to the statistical analysis.
2.5. Statistical Analysis
Data analysis was performed using graphpad.com. Statistical analysis included the
calculation of a 95% confidence interval (95% CI) and assessment of the significance of
differences in values between groups using Fisher’s exact test (significance threshold
p < 0.05).
3. Results
3.1. Hepatitis B Vaccination Coverage in Newborns
The rates of coverage for timely HepB-BD, HepB-2nd and HepB3 per region are shown
in Table 1. In Belgorod Oblast the average rate of HepB-BD coverage was 89.4% (894/1000).
Analysis of the reasons of missed timely HepB-BD showed that in 69% of cases (73/106)
it was due to the refusal of parents to vaccinate their newborns for personal reasons.
Vaccination was not performed for medical reasons in 31% of cases (33/106). The most
common reasons for the medical refusal were prematurity, neonatal jaundice, hemolytic
disease of the newborn, perinatal CNS damage, and combination of these conditions with
other pathologies. In 3 out of 33 cases, mothers declined to vaccinate also after one month,
when medical reasons for non-vaccination subsided.
Cases with no HepB-BD were documented in all eight surveyed medical institutions
in Belgorod Oblast. Of these, 48.1% of cases (51/106) were concentrated in a single clinic. In
this particular clinic, the main reason for not receiving timely HepB-BD was the refusal of
parents to vaccinate children (in 90.2%; 46/51 of the cases). This clinic also demonstrated the
lowest rates of coverage with HepB-BD, HepB-2nd and HepB3 (Table 1, Center B6): 66.0%,
16.3%, and 80.7%, respectively. An investigation of the abnormally low rates of vaccination
coverage in this clinic revealed that an employee who was directly involved in organizing
the vaccination process disseminated negative information regarding vaccination to the
mothers of the newborns.
In Yakutia, 99.2% (2165/2182) of the surveyed children received timely HepB-BD
(Table 1). This coverage indicator was significantly higher than the HepB-BD rate in
Belgorod Oblast (p < 0.0001). A total of 17 cases not receiving timely HepB-BD were
documented in 6 out of 16 surveyed medical centers in Yakutia. Among these cases, ten
(59%) were due to parent refusal, and seven, to medical reasons.
The average HepB3 coverage by one year of age was >90% in both study regions.
This indicator was between 86% and 100% in all surveyed medical centers, except for the
aforementioned clinic B6 (Table 1). In both regions, the lowest rates were observed for
the timely coverage with HepB-2nd. This indicator was below 70% in 13 out 24 surveyed
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clinics (Table 1), indicating that the second dose and, therefore, the third dose of vaccine
were often administered with a delay. However, it should be noted that all children who
received HepB3 before age 1 year, received a second dose of vaccine, either on time or with
a delay.
Table 1. Rates of coverage with timely HepB-BD, timely HepB-2nd and HepB3.




HepB-2nd at 4–6 Weeks
Children Who Received
HepB3 before Age 1 Year
N % N % N %
Belgorod
Oblast
B1 100 94 94.0 51 51.0 99 99.0
B2 100 98 98.0 90 90.0 98 98.0
B3 100 93 93.0 67 67.0 93 93.0
B4 300 287 95.7 165 55.0 273 91.0
B5 100 98 98.0 54 54.0 98 98.0
B6 * 150 99 66.0 25 16.3 121 80.7
B7 50 42 86.0 35 70.0 43 86.0
B8 100 83 83.0 67 67.0 86 86.0
Total 1000 894 89.4 554 55.4 911 91.1
Yakutia
Y1 140 140 100 62 44.3 122 87.1
Y2 208 205 98.6 83 39.9 187 89.9
Y3 100 99 99.0 46 46.0 89 89.0
Y4 363 359 98.9 218 60.1 324 89.3
Y5 100 93 93.0 46 46.0 95 95.0
Y6 100 100 100 54 54.0 97 97.0
Y7 100 100 100 72 72.0 96 96.0
Y8 100 100 100 86 86.0 96 96.0
Y9 104 104 100 79 76.0 100 96.2
Y10 148 148 100 108 73.0 133 89.9
Y11 100 100 100 82 82.0 100 100
Y12 100 100 100 80 80.0 89 89.0
Y13 106 106 100 79 74.5 100 94.3
Y14 100 99 99.0 63 63.0 93 93.0
Y15 213 212 99.5 159 74.6 189 88.7
Y16 100 100 100 95 95.0 98 98.0
Total 2182 2165 99.2 1412 64.7 2008 92.0
* The center with the lowest vaccination coverage rates is indicated in red.
We have also observed differences in hepatitis B vaccine coverage rates depending
on the location of the medical centers. In Belgorod Oblast, rates of coverage with timely
HepB-BD, timely HepB-2nd and HepB3 in city clinics were significantly higher than in
the town clinics (95.3% vs. 80.5%, p < 0.0001; 62.1% vs. 45.2%, p < 0.0001; 93.8% vs. 87.0%,
p = 0.0003, respectively) (Table 2).
In Yakutia, timely HepB-BD coverage rates were similar and above 99% in all types
of centers. Meanwhile, the proportion of children who received timely HepB-2nd varied
from 50.4 to 76.9%, depending on the location of the medical institution. In city centers,
this indicator was significantly lower than in town centers (70.1%, p < 0.0001) and in rural
centers (76.9%, p = 0.0048). The proportion of children who received HepB3 upon reaching
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the age of 12 months was significantly higher in town centers (95.3%) than in city centers
(89%, p ≤ 0.0001) and in rural centers (91.9 %, p = 0.0096).










HepB-2nd at 4–6 Weeks
Children Who Received
HepB3 before Age 1 Year
N % N % N %
Belgorod
Oblast
City 600 572 95.3 373 62.1 563 93.8
Town 400 322 80.5 181 45.2 348 87.0
Yakutia
City 811 803 99.0 409 50.4 722 89.0
Town 752 745 99.1 527 70.1 717 95.3
Rural 619 617 99.7 476 76.9 569 91.9
3.2. Prevalence of Hepatitis B Markers in a Conditionally Healthy Population
The size of the study cohorts corresponded to 0.11% of the total population of each
region, being 1,549,151 people in Belgorod Oblast and 971,996 people in Yakutia [8].
Average HBsAg prevalence rates were significantly higher in Yakutia than in the
Belgorod Oblast (2.2% (24/1072) vs. 0.5% (9/1754), p < 0.01, Fisher exact test). Data
on the prevalence of HBsAg, anti-HBc and anti-HBs in each age group are shown in
Figure 1 and Supplementary Table S1. With the exception of people over 60 years of age,
HBsAg prevalence was consistently higher in Yakutia across all age groups. The HBsAg
positivity rate for subjects over 60 years in Yakutia was similar to the positivity rate in
the corresponding age group in Belgorod Oblast (1.7% and 1.6%, respectively; Figure 2A).
The highest HBsAg positivity rate was observed in Yakutia in children aged 10–14 years
(4.0% (5/125)), however, the difference between this rate and positivity rates in other age
groups in Yakutia was not statistically significant (p > 0.05, Fisher exact test). All HBsAg-
positive serum samples were negative for both HBeAg and anti-HDV. Additionally, we
calculated HBsAg prevalence in women of childbearing age (15–49 years), which was 1.1%
(95% CI: 0.2–3.2%; 3/283) in Yakutia and 0.2% (1/536) in Belgorod Oblast. In Yakutia, this
figure was significantly lower compared to HBsAg prevalence in children aged 0–14 years
(3.5% (4/402), p < 0.05, Fisher exact test). In the Belgorod Oblast, HBsAg prevalence in
children aged 0–14 years was 0.4% (1/238) and tended to be higher compared to women of
childbearing age, but not significantly (p > 0.05, Fisher exact test).
The average prevalence of anti-HBc was significantly higher in Yakutia than in Belgo-
rod Oblast (29.4% (315/1072) vs. 17.1% (300/1754), p < 0.0001, Fisher exact test). Anti-HBc
positivity rates in each age group were significantly higher in Yakutia than in Belgorod
Oblast, with the exception of children in the 0–9 and 10–14 age groups, where seroposi-
tivity rates were similar in Yakutia and in Belgorod Oblast (p > 0.05 for both age groups).
Seropositivity rates increased with age in both regions, but the increase started earlier in
Yakutia, with the 15–19 age group, while in Belgorod the increase started with the 40–49
age group (Figure 2B). It should be noted that according to the questionnaire data, none of
the study participants reported a history of jaundice and/or liver disease.
Figure 2C shows the proportion of samples that were non-reactive for anti-HBc, but
reactive for anti-HBs, i.e., indicating the proportion of participants who had only vaccine-
induced anti-HBs antibodies and were not exposed to HBV. In children under 15 years
of age, the proportion of the population with only vaccine-induced anti-HBs antibodies
varied between 56–67% independently of the region (Belgorod Oblast and Yakutia) or
age of the children. The proportion of population with only vaccine-induced anti-HBs
antibodies among adolescents aged 15–19 and adults aged 20–29 years in Yakutia was
significantly lower than in Belgorod Oblast (p = 0.0056, and p = 0.0002, respectively; Fisher
exact test) (Figure 2C). In older age groups, the proportion of anti-HBs positive, anti-HBc
negative samples declined in both regions in a similar way, but to a significantly lower
Vaccines 2021, 9, 82 8 of 15
level in subjects aged 60 years and older in Belgorod Oblast than in Yakutia (6.3% vs. 31.4%,
p < 0.0001, Fisher exact test; Figure 2C).
We have also assessed the proportion of individuals susceptible to HBV in every age
group as those non-reactive for both anti-HBc and anti-HBs (Figure 2D). It was similar in
individuals under 30 years of age in both Yakutia and Belgorod Oblast, varying from 21.6%
to 35.3% (Figure 2D). In the older age groups, the proportion of potentially susceptible to
HBV individuals remained at the level of 15–16% in Yakutia, but significantly increased in
the Belgorod Oblast (to 45–60%; p < 0.0001, Fisher exact test; Figure 2D).




Figure 2. Proportions of serum samples reactive for hepatitis B markers in each age cohort of conditionally healthy indi-
viduals in the Belgorod Oblast and Yakutia: reactive for HBV surface antigen (HBsAg) (A); reactive for antibodies to HBV 
core antigen (anti-HBc) (B); reactive for antibodies to HBsAg (anti-HBs), but non-reactive for anti-HBc (C); non-reactive 
for either anti-HBs, or anti-HBc (D). 
The average prevalence of anti-HBc was significantly higher in Yakutia than in Bel-
gorod Oblast (29.4% (315/1072) vs. 17.1% (300/1754), p < 0.0001, Fisher exact test). Anti-
HBc positivity rates in each age group were significantly higher in Yakutia than in Belgo-
rod Oblast, with the exception of children in the 0–9 and 10–14 age groups, where sero-
positivity rates were similar in Yakutia and in Belgorod Oblast (p > 0.05 for both age 
groups). Seropositivity rates increased with age in both regions, but the increase started 
earlier in Yakutia, with the 15–19 age group, while in Belgorod the increase started with 
the 40–49 age group (Figure 2B). It should be noted that according to the questionnaire 
data, none of the study participants reported a history of jaundice and/or liver disease. 
Figure 2C shows the proportion of samples that were non-reactive for anti-HBc, but 
reactive for anti-HBs, i.e., indicating the proportion of participants who had only vaccine-
induced anti-HBs antibodies and were not exposed to HBV. In children under 15 years of 
age, the proportion of the population with only vaccine-induced anti-HBs antibodies var-
ied between 56–67% independently of the region (Belgorod Oblast and Yakutia) or age of 
the children. The proportion of population with only vaccine-induced anti-HBs antibodies 
among adolescents aged 15–19 and adults aged 20–29 years in Yakutia was significantly 
lower than in Belgorod Oblast (p = 0.0056, and p = 0.0002, respectively; Fisher exact test) 
(Figure 2C). In older age groups, the proportion of anti-HBs positive, anti-HBc negative 
samples declined in both regions in a similar way, but to a significantly lower level in 
subjects aged 60 years and older in Belgorod Oblast than in Yakutia (6.3% vs. 31.4%, p < 
0.0001, Fisher exact test; Figure 2C). 
We have also assessed the proportion of individuals susceptible to HBV in every age 
group as those non-reactive for both anti-HBc and anti-HBs (Figure 2D). It was similar in 
individuals under 30 years of age in both Yakutia and Belgorod Oblast, varying from 
Figure 2. Proportions of serum samples reactive for hepatitis B markers in each age cohort of conditionally healthy
individuals in the Belgorod Oblast and Yakutia: reactive for HBV surface antigen (HBsAg) (A); reactive for antibodies to
HBV core antigen (anti-HBc) (B); reactive for antibodies to HBsAg (anti-HBs), but non-reactive for anti-HBc (C); non-reactive
f r it r ti- , ti- ( ).
3.3. Attitude to Vaccination among University Students and Teachers
A complete comparative analysis of the responses to interview questions related to
knowledge of and attitude towards vaccination of university students and teachers of
medical versus non-medical specialties is presented in Table 3. Only 45.5% (71/156) of
medical, and 26.1% (164/626, p < 0.0001) of non-medical students and teachers mentioned
HBV as an infection that can be prevented by vaccination. Of the respondents who did not
mention HBV as a vaccine-preventable infection, only 60% (51/85) of medical and 51.1% of
non-medical participants (236/462, p = 0.1560) responded positively to the question “Have
you heard that HBV can be prevented by vaccination?”
The subset of questions regarding attitude to vaccination demonstrated similarly high
levels of ignorance and hesitancy in the respondents with a medical as with a non-medical
background. Only 37.8% (59/156) of medical students and teachers stated that they have no
fears concerning vaccination (Table 3, Question #6), similar to the proportion of participants
of non-medical specialties who gave the same response (p = 0.1273, Fisher exact test). At
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the same time, both categories expressed the same degree of confidence in the quality of
vaccines (Table 3, Question #11; 72.4% and 63.6%, respectively, p = 0.0477, Fisher exact test).
Importantly, high proportion of both medical and non-medical respondents expressed
their trust to the medical personnel performing vaccinations (Table 3, Question #10; 84.6%
and 78.7%, respectively, p = 0.1177, Fisher exact test). At the same time, a considerable
proportion of medical students and teachers were tolerant to those who refuse to vaccinate
themselves and their children; among non-medical respondents, this proportion was even
higher (Table 3, Question #9; 49.7% versus 70.4%, respectively; p < 0.0001, Fisher exact
test). A lack of information on vaccines was mentioned by a majority of participants in
both groups; only 7.9% (62/782) of respondents were satisfied with the information on the
vaccines and vaccination available on the public and/or governmental domains.







n/N * % n/N * %
1. Named vaccination among possible ways to prevent dangerous infections 126/156 80.8% 446/626 71.2%
2. Do you know what vaccination is? Answered “Yes” 150/156 96.2% 468/626 74.8%
3. Named hepatitis B as one of the infections prevented by vaccination (respondents were
not prompted with a list of possible answers) 71/156 45.5% 164/626 26.1%
4. Knew that hepatitis B can be prevented by vaccination (targeted refinement to those
who did not mention HBV in response to Question #3). Answered “Yes” 51/85 60.0% 236/462 51.1%
5. Heard about the National Vaccination Schedule. Answered ”Yes” 87/156 55.8% 229/626 36.6%
6. Vaccination fears (multiple answer choices. a list of possible answers was read out)
a. Have no fears about vaccination 59/156 37.8% 196/626 31.3%
b. Children receive too many vaccines in the first two years of life 12/156 7.7% 62/626 9.9%
c. Vaccines can cause side effects or complications 84/156 53.8% 370/626 59.1%
d. Vaccines can weaken the immune system of children and adults 42/156 26.9% 235/626 37.5%
e. Vaccines can cause disease 31/156 19.9% 155/626 24.8%
f. The ingredients in vaccines are unsafe 12/156 7.7% 83/626 13.3%
g. The long-term effects of vaccines on humans have not been studied 10/156 6.4% 72/626 11.5%
h. Vaccination is against my religious beliefs 1/156 0.6% 7/626 1.1%
j. The quality of vaccines is low 4/156 2.6% 46/626 7.3%
k. Other 5/156 3.2% 21/626 3.4%
7. Have you or your relatives/acquaintances encountered illness/medical complications
in children caused by vaccination? Answered “Yes” 61/156 39.1% 224/626 35.8%
8. Have you or your relatives/acquaintances encountered serious illness that could have
been prevented by vaccination? Answered “Yes” 21/156 13.5% 94/626 15.0%
9. There are people/groups of people who refuse to vaccinate themselves and their children. How do you feel about their decision?
a. I disagree. They risk the health of their children and contribute to the spread of disease 78/155 50.3% 189/617 30.6%
b. I do not care. They are entitled to their opinion 65/155 41.9% 354/617 57.4%
c. I agree with them 10/155 6.5% 62/617 10.0%
d. I haven’t heard anything about this 2/155 1.3% 6/617 1.0%
e. Other 0 0.0% 6/617 1.0%







n/N * % n/N * %
10. Do you trust healthcare providers who vaccinate? (Choose one answer from the list)
a. I completely trust them 53/156 34.0% 180/623 28.9%
b. I mostly trust them 79/156 50.6% 310/623 49.8%
c. No opinion 9/156 5.8% 37/623 5.9%
d. I mostly do not trust them 12/156 7.7% 81/623 13.0%
e. I do not trust them at all 3/156 1.9% 15/623 2.4%
11. Do you trust the quality of vaccines? (Choose one answer from the list)
a. I completely trust the quality of vaccines 39/156 25.0% 129/619 20.8%
b. I mostly trust the quality of vaccines 74/156 47.4% 265/619 42.8%
c. No opinion 24/156 15.4% 96/619 15.5%
d. I mostly do not trust the quality of vaccines 14/156 9.0% 106/619 17.1%
e. I do not trust the quality of vaccines at all 5/156 3.2% 23/619 3.7%
12. What information about vaccinations would you like to receive? (Choose any answers from the list)
a. Information about the usefulness and benefits of vaccination 97/156 62.2% 421/626 67.3%
b. Information about additional vaccines 81/156 51.9% 268/626 42.8%
c. Information about vaccine composition 89/156 57.1% 347/626 55.4%
d. Information about contraindications to vaccination 110/156 70.5% 483/626 77.2%
e. Information about complications after vaccination 107/156 68.6% 488/626 78.0%
f. Information about the manufacturers of vaccines 51/156 32.7% 269/626 43.0%
g. Other 1/156 0.6% 9/626 1.4%
h. I have enough information 17/156 10.9% 45/626 7.2%
* n—number of respondents who answered the question; N—number of respondents who were asked the question.
4. Discussion
Vaccination of newborns against hepatitis B is the main tool for controlling this
infection and is a cornerstone of the WHO global health sector strategy on viral hepatitis [5].
In 2015, global coverage of timely HepB-BD was 39%. To achieve the WHO elimination
strategy targets, it should be increased to 50% in 2020, and 90% in 2030. Coverage with a
complete vaccination with three doses (HepB3) is another key indicator of the successful
immunization program, and to control HBV spread it must reach 90% by 2020 [1]. Normally,
hepatitis B vaccination program does not involve monitoring of the antibody response,
since HBV vaccine is highly immunogenic and does not require additional immunizations,
at least in the immunologically competent individuals who have received HepB3 [12].
It is assumed that seroprotection rates following the hepatitis B vaccination of infants
are equal to or only marginally lower than HepB3 coverage, as the complete course of
immunization induces protective antibody concentrations in >95% of healthy infants,
children and young adults [13,14]. However, data from the real-world practice indicate that
the actual seroprotection rates are much lower. In our study, the proportion of individuals
who did not have vaccine-induced or post-infection immunity among the vaccinated
generation (birth cohort 1998–2019; where officially reported HepB3 coverage is >95%)
was more than 25% [3]. Also, the proportion of children under 10 years of age who have
the vaccine-induced immunity (are anti-HBc-negative and have not contracted the virus)
was below 60%. This is unexpectedly low, even considering that anti-HBs may wane
with time. In China, the anti-HBs positivity rate among children who did not receive
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any booster immunization was 60.9% on average and declined with age from to 75.2%
in children born in 2002–2003 to 44.3% in those born in 2012–2013 [15]. In a study by Le
et al., vaccine-induced immunity to HBV among US-born children varied from 60.7% to
65.2% in children aged 2 to 5 years and from 46.5% to 64.6% in children aged 6 to 10 years,
depending on the birth cohort. Interestingly, the rates of vaccine-associated immunity in
this study significantly decreased in the 1994–2003 birth cohort on contrary to those in the
children vaccinated earlier (1988–1993 birth cohort) [16].
Detection rates of anti-HBc antibodies, indicating exposure to HBV, in the 1998–2019
birth cohort are alarmingly high, varying from 8% to 18%, depending on the geographical
region and age group. Moreover, the prevalence of HBsAg in Yakutia is not significantly
lower for those born between 1998 and 2019 when compared to older age groups, sug-
gesting the limited impact of vaccination on HBV prevalence in the region. Such anti-HBc
positivity rates in the vaccinated generation, together with relatively low HBsAg preva-
lence and the absence of a self-reported history of jaundice or liver disease, suggest that
a significant proportion had a self-limited subclinical infection in vaccinated individuals,
i.e., an ongoing circulation of HBV in the vaccinated generation born between 1998 and
2019. The plausible explanation of our data is vertical HBV transmission from the infected
mothers. In Russia, testing of all pregnant women for HBsAg is mandatory. All HBsAg
positive pregnant women are further tested for HBeAg and HBV viral load to assess the risk
of vertical transmission. Unfortunately, records on HBV status of mothers of participants
of this serosurvey at the time of delivery were not available. WHO recommends tenofovir
prophylaxis of mother-to child transmission in pregnant women with HBV viral load above
200,000 IU/mL [17], but this effective measure is not yet applied in Russia. Neither is
HBIG administration to children born to HBV infected mothers. The only intervention for
children born to HBV infected mothers in Russia is four doses immunization at months 0, 1,
2 and 12 compared to standard vaccination schedule for children born to HBsAg negative
mothers (0, 1 and 6 months) [18]. In this context, vertical HBV transmission cannot be
excluded. However, the vertical transmission alone could not account for high HBsAg
prevalence in the birth cohort born after the start of universal vaccination program in
Yakutia. HBsAg positivity rates in adult population, including those observed in women
of childbearing age, were lower compared to children aged 0–14 years. Thus, other trans-
mission routes and risk factors may contribute to ongoing HBV circulation in children and
adolescents, which requires further study.
Earlier, we showed that vaccination against hepatitis B in several regions of Russia,
including Yakutia, led to a significant decrease in the incidence and prevalence of HBV
in the general population and the number of expected unfavorable outcomes of the infec-
tion [10]. Unfortunately, today, ten years after this study, we see no further pronounced
decline in HBsAg detection in the general population of Yakutia (although the sample size
in our study might be not large enough to reliably characterize the exact prevalence of
HBsAg or anti-HBc antibodies in every age cohort in the region). Furthermore, we observe
relatively low anti-HBs detection rates in the vaccinated-at-birth cohort. Such low levels
cannot be attributed to the low sensitivity of the test used, as the detection limit for our
anti-HBs test was 1 mIU/mL, according to the manufacturer’s manual. Nor can such low
seroprotection rates be due to waning of the vaccine-induced immunity, since the rates of
anti-HBs seropositivity in children aged 10–14 were found to be similar or even slightly
higher than in children aged 0–9 years.
It is also highly unlikely that insufficient immune response to HBV vaccination was
due to the poor vaccine quality. According to the information provided by the agency re-
sponsible for the quality of products in the Russian Federation (Rospotrebnadzor) = HBV
vaccination is performed with as many as six hepatitis B vaccines of the renown inter-
national manufacturers and five national vaccines, all licensed for use in the Russian
Federation [19]. All vaccines are wildly used and recognized as interchangeable, with
trials demonstrating similar immunogenicity [20]. Furthermore, each series of home-
produced vaccines undergo the quality control, which includes, but is not limited to, the
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determination of sedimentation stability, pH, sterility, absence of bacterial endotoxins,
pyrogenicity, toxicity, concentration of HBsAg in vaccine, immunogenicity tested in vivo,
and completeness of antigen sorption [21].
One of the reasons for reduced vaccine-induced immunity to HBV could be partial
inactivation of the vaccine preparations due to faults in the vaccine cold chain. Freezing a
vaccine results in the loss of its immunogenicity [22,23]. Thus, vaccination in regions with
harsh winters may be less effective during the winter due to improper transportation and
storage conditions, as has been described for HBV vaccination performed in Mongolia [24].
The other highly plausible explanation for a bias between relatively low anti-HBs
(and high anti-HBc antibody) and the officially reported HepB3 coverage could be vac-
cination gaps (uncompleted or not timely vaccinations), which facilitate mother-to-child
or horizontal transmissions during the first year of life. The vaccination coverage data
obtained in our study from vaccination records stored at clinics appear to be representative,
since home birth is not a common practice in Russia, while the vast majority of births take
place in maternity hospitals, except for indigenous nomadic population in some regions
of the country [25]. The majority of children are not missed for the assignment to clinics
and have vaccination records (Form 63), as the latter is a mandatory document for further
admission to kindergarten and school. Thus, we assume the risk of the overestimation
of the vaccination coverage to be minimal in this study. Our data from the real-world
practice demonstrate that in some perinatal centers the coverage rates could be significantly
lower than the average rates for the region, even for the region with satisfactory indicators
of the average coverage. Even if HepB3 coverage reaches the WHO target indicator in
infants by one year of age, rates of coverage with HepB-BD and timely administration of
HepB-2nd can vary greatly between clinics and may be below the expected 90% coverage
rate. Timely HepB-2nd coverage was only 55.4%–64.7%, suggesting that a delay in the
vaccination schedule could be a widespread practice. In one particular clinic in this study,
timely HepB-BD coverage was only 66%. We came across only one clinic with grossly
malfunctioning vaccination practices, but there could be more. Timeliness of HepB-2nd
was shown to be critical for protection of infants against horizontal HBV transmission [26].
Late provision of 2nd and 3rd vaccine doses puts children at a risk of HBV infection before
receiving the complete vaccination course, specifically in the regions of high endemicity,
where they may acquire HBV from the infected members of the household. Earlier studies
revealed strong associations of HBV transmission among children with sharing of the
personal objects (sharp objects, dishes, cutlery, glasses, face towels, and toothbrush) with
HBV-infected family members [27], specifically mothers [28]. Importantly, continued HBV
circulation creates favorable conditions for further spread of the virus to non-vaccinated
individuals, and can potentially result in the spread in the 1998–2019 birth cohort of HDV,
especially in Yakutia, where this infection is highly prevalent [29]. Altogether, published
data and our findings stress the importance of strict adherence to vaccination schedule and
the necessity of full HBV vaccination with three doses, to prevent this scenario.
Investigation of the reasons for the low rates of vaccination coverage in a particular
clinic, demonstrated that a doctor directly involved in the vaccination process negatively
impacted mothers’ decisions to vaccinate their newborns. It has been previously shown
that health care providers have strong influence on the decision of parents to vaccinate their
children, and that a positive influence results in significantly higher estimated coverage
rates [30]. Our data further supports the significance of health workers’ influence on the
frequency of parental refusal to vaccinate, and the necessity to train personnel organizing
and performing HBV vaccination.
The average proportion of parental refusal in our study was as high as 67.5% among
all cases of missed timely HepB-BD. Data from all over the world suggest that the main
reasons for low HepB-BD coverage are parental concerns on vaccination safety and a lack
of information [31–33]. To find out if this is true in the settings of this study, we conducted
a survey of the university students and teachers, from both medical and non-medical
specialties, aimed to characterize their attitudes to vaccines and vaccination, including
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vaccination against hepatitis B. Our survey revealed that alarmingly low proportion of
medical students and teachers (only 60%) were aware that hepatitis B can be prevented
by vaccination. Furthermore, the proportion of medical students and teachers concerned
about vaccination safety amounted to 63%, being disturbingly similar to the proportion of
non-professionals with the same opinion. These figures manifest strong vaccine hesitancy
prevailing in different layers of the Russian population. Such hesitancy is a serious concern
in the current epidemiological situation characterized by free circulation of HBV in the
general population, as it endangers the implementation of hepatitis B elimination program.
Health professional education programs need to be revised to emphasize the importance of
vaccination, and hold healthcare providers accountable for participation in anti-vaccination
campaigns and disseminating vaccination misinformation. Moreover, special vaccine audit
programs aimed at random monitoring of vaccination coverage and determination of
vaccine-induced herd immunity might be beneficial to estimate the true protection rates.
5. Conclusions
The most important result of our serosurvey is that the proportion of the protected
individuals in the vaccinated generation in a region highly endemic for HBV is below
expectations and insufficient to stop HBV circulation. Our data demonstrate the presence
of gaps in the coverage of HepB-BD and timely administration of HepB-2nd in real-world
practice despite high HEPB3 coverage in children by one year of age. Such gaps could
be due to faults in the vaccine delivery cold chain and/or inadequate performance of the
medical personal responsible for vaccination, but mainly are associated with the parental
refusal to vaccinate their children. The latter, however, may result from the hesitancy
towards vaccination of the health care providers. Our observations are supported by the
lack of knowledge about hepatitis B vaccination and fears of vaccination demonstrated in
the representative interviews done among medical students and teachers. Such settings
lead to a reduced rate of HBV vaccination coverage resulting in an ongoing circulation of
HBV among the vaccinated-at-birth cohort, both in the endemic and non-endemic regions
of the Russian Federation. This unfavorable situation indicates the need to introduce a
vaccine audit system aimed at monitoring hepatitis B vaccination coverage and vaccine-
induced immunity, as well as strongly improve medical education in the field of vaccines
and vaccinations.
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